Effectiveness of a new bladder cancer treatment demonstrated
It involves an inhibitor of a dual protein, mTORC1/2, which is key in tumour growth
Good results in patients
The clinical trial, which evaluated seven patients, reports that four of these showed a positive response to the drug. In these sufferers, tumour growth was slowed and tumour progression avoided. These were metastatic bladder cancer patients who did not respond to the usual treatments, including immunotherapy.
Currently in the United States, only one treatment for a bladder cancer molecular target has been approved. It is a unique treatment, differing from chemotherapy or radiation therapy. Dr. Bellmunt highlights this fact, pointing out that. This studied drug could become a second potential therapeutic target in bladder cancer patients. It is not chemotherapy, radiotherapy, or immunotherapy, but it attacks specific genetic alterations found in tumours.
Hernández A, Rodríguez-Vida A, Juanpere N, Arpí O, Menéndez S, Soria-Jiménez L, Martínez-Fernández A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J. Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models. Mol Canc Res 2019; 17(9): 1931-1944.